At Janssen, we are committed to helping people living with HIV in resource-limited settings by ensuring effective and sustainable access to our HIV medicines, or antiretrovirals (ARVs). We believe that effective HIV drug access has two important components: ensuring quality and affordable medicines are available sustainably and that they are used safely and in the most appropriate way for people living with HIV/AIDS (PLWHA).
Through our comprehensive HIV drug access framework, our Global Access and Partnerships Program works to fulfill this responsibility to PLWHA in resource-limited countries, such as in sub-Saharan Africa (SSA), least developed countries (LDCs), and lower middle-income countries (LMICs). This includes:
- Operating on a sustainable, not-for-profit basis
- Licensing for both branded and generic versions of our HIV medicines
- Prioritizing regulatory filings where there is a public health need
- Supporting the optimal, appropriate and safe use of our HIV medicines